Macrophage: SHIP of immunity

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Mills, Charles D ^a   Thomas, Anita C ^b   Lenz, Laurel L ^c   Munder, Markus ^d  

^a BioMedical Consultants   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Arginase; Cancer; iNOS; M1; M2; Macrophage; Nitric oxide; Wound

Indexed keywords

ANTIGEN; ARGININE; CD11B ANTIGEN; CD40 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; ORNITHINE; SHIP ANTIGEN; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BIOCHEMISTRY; CELL METABOLISM; CELL REGENERATION; HUMAN; INFECTION; INJURY; INNATE IMMUNITY; MACROPHAGE; METABOLOMICS; MICROFLORA; NONHUMAN; PLASTICITY; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; TUMOR GROWTH; TUMOR REJECTION;

EID: 84919773477     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00620     Document Type: Article

References (60)

1. Mills CD, Ley K. M1 and M2 macrophages: the chicken and the egg of immunity. J Innate Immun (2014) 6:716-26. doi:10.1159/000364945
2. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature (2013) 496:445-55. doi:10.1038/nature12034
3. Mills CD. M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol (2012) 32:463-88. doi:10.1615/CritRevImmunol.v32.i6.10
4. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science (2010) 327:656-61. doi:10.1126/science.1178331
5. Cooper EL. eCAM: Darwin and Metchnikoff. Evid Based Complement Alternat Med (2009) 6:421-2. doi:10.1093/ecam/nep194
6. Dzik JM. The ancestry and cumulative evolution of immune reactions. Acta Biochim Pol (2010) 57:443-66.
7. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (2000) 164:6166-73. doi:10.4049/jimmunol.164.12.6166
8. Morris SM. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol (2009) 6:922-30. doi:10.1111/j.1476-5381.2009.00278.x
9. Munder M. Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol (2009) 158:638-51. doi:10.1111/j.1476-5381.2009.00291.x
10. Hibbs JB, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun (1988) 157:87-94. doi:10.1016/S0006-291X(88)80015-9
11. Nathan CF. Nitric oxide as a secretory product of mammalian cells. FASEB J (1992) 12:3051-64.
12. Mills CD. Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Crit Rev Immunol (2001) 21:399-426. doi:10.1615/CritRevImmunol.v21.i5.10
13. Albina JE, Mills CD, Henry WL Jr, Caldwell MD. Temporal expression of different pathways of 1-arginine metabolism in healing wounds. J Immunol (1990) 144:3877-80.
14. Mills CD, Shearer J, Evans R, Caldwell MD. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol (1992) 149:2709-14.
15. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci (2014) 105:1-8. doi:10.1111/cas.12314
16. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 41:49-61. doi:10.1016/j.immuni.2014.06.010
17. Tang X, Mo C, Wang Y, Wei D, Xiao H. Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology (2012) 138:93-104. doi:10.1111/imm.12023
18. Weigert A, Brune B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide (2008) 2:95-102. doi:10.1016/j.niox.2008.04.021
19. Nathan C. Role of iNOS in human host defense. Science (2006) 312:1874-5. doi:10.1126/science.312.5782.1874b
20. Hibbs JB. Infection and nitric oxide. J Infect Dis (2002) 185:S9-17. doi:10.1086/338005
21. Vogel SN, Johnson D, Perera PY, Medvedev A, Lariviere L, Qureshi ST, et al. Cutting edge: functional characterization of the effect of the C3H/HeJ defect in mice that lack an Lpsn gene: in vivo evidence for a dominant negative mutation. J Immunol (1999) 162:5666-70.
22. Reiss CS, Komatsu T. Does nitric oxide play a critical role in viral infections? J Virol (1998) 78:4547-51.
23. Stevens RB, Ansite JD, Mills CD, Lokeh A, Rossini TJ, Saxena M, et al. Nitric oxide mediates early dysfunction of rat and mouse islets after transplantation. Transplantation (1996) 12:1740-9. doi:10.1097/00007890-199606270-00014
24. Albina JE, Caldwell MS, Henry WL, Mills CD. Regulation of macrophage functions by L-arginine. J Exp Med (1989) 169:1021-9. doi:10.1084/jem.169.3.1021
25. Nathan CF. Secretory products of macrophages. J Clin Invest (1987) 79:319-26. doi:10.1172/JCI112815
26. Hibbs JB, Vavrin Z, Taintor RR. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol (1987) 138:550-65.
27. Li Y, Karlin A, Loike JD, Silverstein SC. Determination of the critical concentration of neutrophils required to block bacterial growth in tissues. J Exp Med (2004) 200:613-22. doi:10.1084/jem.20040725
28. Filipin L, Moreira AJ, Marroni NP, Xavier RM. Nitric oxide and repair of skeletal muscle injury. Nitric Oxide (2009) 3:157-63. doi:10.1016/j.niox.2009.08.002
29. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol (2011) 11:723-37. doi:10.1038/nri3073
30. Geissmann F, Gordon S, Hume DA, Mowat DA, Randolph GJ. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol (2010) 10:453-60. doi:10.1038/nri2784
31. Hume DA. Macrophages as APC and the dendritic cell myth. J Immunol (2008) 181:5829-35. doi:10.4049/jimmunol.181.9.5829
32. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature (2007) 449:419-26. doi:10.1038/nature06175
33. Hsieh CS, Macatonia SE, O'Garra A, Murphy KM. T cell genetic background determines default T helper phenotype development in vitro. J Exp Med (1995) 181:713-21. doi:10.1084/jem.181.2.713
34. O'Garra A, Murphy KM. Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol (1994) 6:458-66. doi:10.1016/0952-7915(94)90128-7
35. Beutler BA. TLRs and innate immunity. Blood (2009) 113:1399-407. doi:10.1182/blood-2008-07-019307
36. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 34:637-50. doi:10.1016/j.immuni.2011.05.006
37. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol (2002) 20:197-216. doi:10.1146/annurev.immunol.20.083001.084359
38. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia (2009) 11:615-28. doi:10.1593/neo.09284
39. Matzinger P. An innate sense of danger. Ann N Y Acad Sci (2002) 961:341-2. doi:10.1111/j.1749-6632.2002.tb03118.x
40. Mackaness GB. The immunologic basis of acquired cellular resistance. J Exp Med (1964) 120:105-20. doi:10.1084/jem.120.1.105
41. Shevach EM, Rosenthal AM. Function of macrophages in antigen recognition by guinea pig T lymphocytes. II. Role of the macrophage in the regulation of genetic control of the immune response. J Exp Med (1973) 138:1213-29. doi:10.1084/jem.138.5.1213
42. Unanue ER. Antigen-presenting function of the macrophage. Annu Rev Immunol (1984) 2:395-428. doi:10.1146/annurev.iy.02.040184.002143
43. Dorrestein PC, Mazmanian SK, Knight R. Finding the missing links among metabolites, microbes, and the host. Immunity (2014) 40:824-32. doi:10.1016/j.immuni.2014.05.015
44. Bae YS, Lee JH, Choi SH, Kim S, Almazan F, Witztum JL, et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4-and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res (2009) 104:210-8. doi:10.1161/CIRCRESAHA.108.181040
45. Nathan CF. Macrophage activation: some questions. Ann Inst Pasteur Immunol (1986) 137:345-51. doi:10.1016/S0771-050X(86)80051-1
46. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (1993) 260:547-9. doi:10.1126/science.8097338
47. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med (1998) 12:2103-8. doi:10.1084/jem.187.12.2103
48. Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. CD40 ligation activates murine macrophage via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol (2005) 174:6013-22. doi:10.4049/jimmunol.174.10.6013
49. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 8:958-69. doi:10.1038/nri2448
50. Fleming BD, Mosser DM. Regulatory macrophages: setting the threshold for therapy. Eur J Immunol (2011) 41:2498-502. doi:10.1002/eji.201141717
51. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 25:677-86. doi:10.1016/j.it.2004.09.015
52. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med (1992) 176:287-92. doi:10.1084/jem.176.1.287
53. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol (2006) 177:7303-11. doi:10.4049/jimmunol.177.10.7303
54. Daley JM, Brancato SK, Thomay AA, Reichner JS, Albina JE. The phenotype of murine wound macrophages. J Leukoc Biol (2010) 87:59-67. doi:10.1189/jlb.0409236
55. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med (2012) 18:1028-40. doi:10.1038/nm.2807
56. Bogdan C. Species differences in macrophage NO production are important. Nat Immunol (2002) 3:102. doi:10.1038/ni0202-102a
57. Fang FC, Nathan C. Man is not a mouse: reply. J Leukoc Biol (2007) 81:580. doi:10.1189/jlb.1206715
58. Thomas A, Matilla J. Of mice and men: arginine metabolism in macrophages. Front Immunol (2014) 5:479. doi:10.3389/fimmu.2014.00479
59. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 41:14-20. doi:10.1016/j.immuni.2014.06.008
60. Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol (2004) 76:509-13. doi:10.1189/jlb.0504272